9 completed, 1 unknown. 6 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 5, Unknown 1 |
| Phase 1 | 4 | Completed 4 |
Follow lesogaberan: new trials by email Literature Review of lesogaberan trials Research Report on lesogaberan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lesogaberan in Chinese Patients With Refractory Reflux Symptoms Lesogaberan, Placebo - Gastroesophageal Reflux Disease | Phase 2 | Unknown | National Taiwan University Hospital | 72 | 2015-01-01 | 2016-06-29 |
| A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience AZD3355, placebo - Gastroesophageal Reflux Disease | Phase 2 | Completed | AstraZeneca | 27 | 2009-12-01 | 2011-06-14 |
| Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI lesogaberan (AZD3355), Placebo - Gastroesophageal Reflux Disease, Heartburn | Phase 2 | Completed | AstraZeneca | 661 | 2009-10-01 | 2011-04-25 |
| Renal Impairment Study AZD3355 - Reflux, Renal Excretion | Phase 1 | Completed | AstraZeneca | 23 | 2009-03-01 | 2011-01-24 |
| AZD3355 Dose-escalation Study in Healthy Males AZD3355, Placebo - Reflux Disease | Phase 1 | Completed | AstraZeneca | 54 | 2008-09-01 | 2010-12-07 |
| Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms AZD3355, Placebo, Gelusil® - GERD, Acid Reflux Disease | Phase 2 | Completed | AstraZeneca | 478 | 2008-05-01 | 2011-06-20 |
| Study to Compare Different Formulations of AZD3355 AZD3355 - Gastroesophageal Reflux Disease | Phase 1 | Completed | AstraZeneca | 48 | 2008-04-01 | 2010-12-03 |
| Drug Interaction Study Between AZD3355 and Nexium AZD3355, Esomeprazole - Gastroesophageal Reflux Disease | Phase 1 | Completed | AstraZeneca | 30 | 2008-03-01 | 2010-12-03 |
| TLESR-impedance Study in Patients AZD3355, Placebo - Reflux Episodes | Phase 2 | Completed | AstraZeneca | 27 | 2007-02-01 | 2013-07-22 |
| Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients AZD3355 - Gastroesophageal Reflux Disease (GERD) | Phase 2 | Completed | AstraZeneca | 244 | 2006-11-01 | 2013-03-18 |
Gastroesophageal Reflux (10) · Heartburn (3)
AstraZeneca (9) · National Taiwan University Hospital (1)
Sweden (4) · United States (3) · Australia (1) · Belgium (1) · France (1) · Germany (1) · Hungary (1) · Netherlands (1) · Norway (1) · Romania (1) · Taiwan (1)
Eva Ersdal, PhD (3) · Debra Silberg, MD (2) · Aslak Rautio, MD (1) · Daniel Sifrim, MD, PhD (1) · Debra G Silberg (1) · Eva Ersdal (1) · Guy Boeckxstaens, MD (1) · Jan Vouis, MD (1) · Marianne Hartford (1) · Nicholas Shaheen, MD, MPH (1) · Nimish Vakil, MD (1) · Philip Miner (1) · Ping-Huei Tseng, MD, PhD (1) · Wolfgang Kuhn, MD (1)
PMID 20451523, PMID 21171670, PMID 21402616, PMID 22730470, PMID 23318482, PMID 23919738, PMID 25304129, PMID 25407279, PMID 27712711